Allergy Therapeutics presents progress at AAAAI

AI SummaryClose X

Allergy Therapeutics plc announced scientific progress at the 2026 AAAAI Annual Meeting, presenting positive biomarker and clinical data for Grass MATA MPL, which showed a statistically significant improvement of -22.5% in Combined Symptom Medication Score compared to placebo across Phase III trials, supporting its efficacy and tolerability for seasonal allergic rhinitis. The company also shared supportive short-term safety data from a paediatric cohort in the G308 Phase III trial, demonstrating a benign safety profile, and positive interim data for VLP Peanut, its short-course peanut allergy immunotherapy candidate, indicating its potential as a promising therapeutic. No new material price-sensitive information will be disclosed at the meeting.

Disclaimer*

UK 100

Latest directors dealings